It’s the latest fallout from an investigation by Harvard and Brigham and Women’s into work overseen by Piero Anversa.

Since their discovery in 2006, induced pluripotent stem cells have been poised to reprogram regenerative medicine. Twelve years on, here’s how far they’ve come.

This is the first time researchers have tested the use of the reprogrammed stem cells in the human brain.

A trial to test whether so-called c-kit cardiac stem cells, first reported by Piero Anversa, could help patients with chronic heart failure has been halted in light of suspicion surrounding his work.

Investigators have launched numerous clinical trials that test the efficacy of the immunotherapy. Here is a global accounting of these experiments.

Surgeons will inject approximately 5 million dopamine-producing progenitor cells into patients’ brains.

Researchers plan to turn cancer cells into defectors, engineering them to kill the tumors from whence they came, and have tested the approach in mice.

Stem-cell–derived natural killer cells engineered in a similar way to CAR-T cells may pave the way to “off the shelf” cancer therapies that aren’t patient-specific.

The miniscule carriers successfully transported and released live cells at a particular location within living mice.